Escient Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for mast cell-mediated disorders including chronic urticaria, cholestatic pruritus, and atopic dermatitis. Its lead program EP262 targeted MRGPRX2 receptors. Escient was acquired by Incyte Corporation for $750 million in 2024.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountApr 2024
Nov 2022
Sep 2020
May 2018
Create a free account to see which investors have funded this company.
Create Free AccountIntarcia Therapeutics is a biopharmaceutical company based in Boston, MA, dedicated to developing...
Painless, convenient transdermal patient administration of therapeutic proteins and vaccines
Biotech developing in vivo CAR-T cell therapies. Acquired by AbbVie for $2.1B upfront in 2024.
Biopharmaceutical company focused on virology, oncology, and inflammation therapeutics.
Biotech developing EPiC peptide compounds to cross the blood-brain barrier for treating brain dis...
